On June 26, 2019, the Louisiana Department of Health (DOH) and the Louisiana Department of Corrections (DOC) launched a new hepatitis C payment model with Asegua Therapeutics, LLC, a subsidiary of Gilead Sciences, Inc. The Centers for Medicare & Medicaid Services (CMS) approved a Medicaid State Plan Amendment (SPA) to allow the state to implement a modified subscription arrangement in which the state will pay Asegua Therapeutics a monthly rate to provide an unrestricted amount of Asegua’s direct-acting antiviral, the authorized generic of Epclusa®. The medication will be used to treat Medicaid and DOC populations. The SPA allows . . .